WallStreetZen

NASDAQ: AZN
Astrazeneca Plc Stock Forecast, Predictions & Price Target

Analyst price target for AZN

Based on 4 analysts offering 12 month price targets for Astrazeneca Plc.
Min Forecast
$56.00+5.16%
Avg Forecast
$63.85+19.91%
Max Forecast
$69.40+30.33%

Should I buy or sell AZN stock?

Strong Buy
Strong Buy
5 analysts 71.43%
Buy
0 analysts 0%
Hold
2 analysts 28.57%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Forecast return on equity

Is AZN forecast to generate an efficient return?
Company
45.19%
Industry
75.54%
Market
61.82%
AZN's Return on Equity is forecast to be high in 4 years (45.19%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is AZN forecast to generate an efficient return on assets?
Company
8.59%
Industry
16.98%
Market
19.68%
AZN is forecast to generate lower Return on Assets (8.59%) than the US Drug Manufacturers - General industry average (16.98%)
Forecast

AZN earnings per share forecast

What is AZN's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$2.59+172.89%
Avg 2 year Forecast
$4.42+365.61%
Avg 3 year Forecast
$3.73+292.11%
AZN's earnings are forecast to grow at an exceptional rate of 65.83% per year
Forecast

AZN revenue forecast

What is AZN's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$31.0B+19.94%
Avg 2 year Forecast
$35.3B+36.46%
Avg 3 year Forecast
$39.2B+51.45%
AZN's revenue is forecast to grow at a rate of 14.84% per year, which is not exceptional
Forecast

AZN earnings growth forecast

How is AZN forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
65.83%
Industry
25.04%
Market
20.34%
AZN's earnings are forecast to grow faster (65.83% per year) than the US Drug Manufacturers - General industry average (25.04%)
Forecast
AZN's earnings are forecast to grow faster (65.83% per year) than the US market average (20.34%)
Forecast
AZN's earnings are forecast to grow faster (65.83% per year) than the risk-free savings rate (1.1%)
Forecast

AZN revenue growth forecast

How is AZN forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
14.84%
Industry
6.45%
Market
14.82%
AZN's revenues are forecast to grow faster (14.84% per year) than the US Drug Manufacturers - General industry average (6.45%)
Forecast
AZN's revenues are forecast to grow faster (14.84% per year) than the US market average (14.82%)
Forecast

Astrazeneca Stock Forecast FAQ

Is Astrazeneca Stock a good buy in 2020, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: AZN) stock is to Strong Buy AZN stock.

Out of 7 analysts, 5 (71.43%) are recommending AZN as a Strong Buy, 0 (0%) are recommending AZN as a Buy, 2 (28.57%) are recommending AZN as a Hold, 0 (0%) are recommending AZN as a Sell, and 0 (0%) are recommending AZN as a Strong Sell.

What is AZN's Price Target?

According to 4 Wall Street analysts that have issued a 1 year AZN price target, the average AZN price target is $63.85, with the highest AZN stock price forecast at $69.40 and the lowest AZN stock price forecast at $56.00.

On average, Wall Street analysts predict that Astrazeneca's share price could reach $63.85 by Jan 20, 2022. The average Astrazeneca stock price prediction forecasts a potential upside of 19.91% from the current AZN share price of $53.25.

What is AZN's earnings growth forecast for 2021-2023?

(NASDAQ: AZN) Astrazeneca's forecast annual earnings growth rate of 65.83% is forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 25.04%, and and it is also forecast to beat the US market's average forecast earnings growth rate of 20.34%.

Astrazeneca's earnings in 2020 is $2,416,000,000.On average, 4 Wall Street analysts forecast AZN's earnings for 2021 to be $3,401,360,000, with the lowest AZN earnings forecast at $3,201,280,000, and the highest AZN earnings forecast at $3,673,600,000. On average, 3 Wall Street analysts forecast AZN's earnings for 2022 to be $5,803,369,600, with the lowest AZN earnings forecast at $4,185,280,000, and the highest AZN earnings forecast at $8,987,200,000.

In 2023, AZN is forecast to generate $4,887,200,000 in earnings, with the lowest earnings forecast at $4,723,200,000 and the highest earnings forecast at $5,051,200,000.

What is AZN's revenue growth forecast for 2021-2023?

(NASDAQ: AZN) Astrazeneca's forecast annual revenue growth rate of 14.84% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.45%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 14.82%.

Astrazeneca's revenue in 2020 is $25,871,000,000.On average, 2 Wall Street analysts forecast AZN's revenue for 2021 to be $40,710,048,000,000, with the lowest AZN revenue forecast at $39,949,088,000,000, and the highest AZN revenue forecast at $41,471,008,000,000. On average, 2 Wall Street analysts forecast AZN's revenue for 2022 to be $46,318,192,000,000, with the lowest AZN revenue forecast at $45,450,304,000,000, and the highest AZN revenue forecast at $47,186,080,000,000.

In 2023, AZN is forecast to generate $51,406,128,000,000 in revenue, with the lowest revenue forecast at $50,691,744,000,000 and the highest revenue forecast at $52,120,512,000,000.

What is AZN's Earnings Per Share (EPS) forecast for 2021-2023?

(NASDAQ: AZN) Astrazeneca's current Earnings Per Share (EPS) is $0.95. On average, analysts forecast that AZN's EPS will be $2.59 for 2021, with the lowest EPS forecast at $2.44, and the highest EPS forecast at $2.80. On average, analysts forecast that AZN's EPS will be $4.42 for 2022, with the lowest EPS forecast at $3.19, and the highest EPS forecast at $6.85. In 2023, AZN's EPS is forecast to hit $3.73 (min: $3.60, max: $3.85).

What is AZN's forecast return on equity (ROE) for 2021-2024?

(NASDAQ: AZN) forecast ROE is 45.19%, which is considered strong.

What is AZN's forecast return on assets (ROA) for 2021-2024?

(NASDAQ: AZN) forecast ROA is 8.59%, which is lower than the forecast US Drug Manufacturers - General industry average of 16.98%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics